IPPRA / Grant Monitor

2026-07-07
← Board

Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required)

PAR-24-312 · National Institutes of Health

biomedical clinical public health agriculture food Health

Closes
2026-07-14 · 7 d
Award ceiling
Award floor
Program funding
Expected awards
Cost sharing
No
Posted
2024-10-29
Instrument
Cooperative Agreement
Characterization · gpt-5.4-mini · 2026-07-07

NIH will fund a milestone-driven Clinical Coordinating Center to plan and run a multi-site investigator-initiated Phase III-plus clinical trial of natural products in NCCIH priority areas, with a separate required Data Coordinating Center application submitted at the same time.

Funds
applied research
University
direct
social behavioral
minor
physical sciences
minor
engineering
minor
life biomedical
central
computational data
substantial

⚑ UG3/UH3 two-phase milestone-driven cooperative agreement · Clinical Coordinating Center must be paired with a separate Data Coordinating Center application under PAR-24-125 and submitted simultaneously · Foreign organizations are listed as eligible, but non-domestic components of U.S. organizations are not eligible; foreign components are allowed · Phase III and beyond only; investigator-initiated multi-site clinical trials of natural products in NCCIH priority areas

Unit fits — one characterization, each unit's own rules

Physical Sciences & Engineering (demo) 70 strong technical depth: substantial; funds applied research
IPPRA 58 good portfolio topic: public_health; social/behavioral work is minor; funds applied research; clinical-trial/biomedical core — IPPRA angle is policy/community (capped)
Tom Love Innovation Hub 30 weak funds applied research; deep-tech content

Description

This Notice of Funding Opportunity (NOFO) encourages cooperative agreement applications for investigator-initiated, multi-site, clinical trials (Phase III and beyond) to study the effects of natural products (i.e. botanicals, probiotics, and products marketed as dietary supplements) in NCCIH designated areas of high research priority. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Applicants should describe plans for a Clinical Coordinating Center to develop and implement the proposed multi-site clinical trial. The objective of the Clinical Coordinating Center application is to provide the scientific rationale and a comprehensive scientific and operational plan for the clinical trial. Clinical Coordinating Center applications are expected to describe plans for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. Clinical Coordinating Center applications submitted under this NOFO will utilize a two-phase, milestone-driven, cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying Data Coordinating Center application, submitted under PAR-24-125, proposing a data analysis and data management plan for the clinical project is required. Both a Clinical Coordinating Center application and a corresponding Data Coordinating Center (DCC) application need to be submitted simultaneously for consideration by NCCIH. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (https://nccih.nih.gov/about/plans).

Eligibility

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Apply

View on Grants.gov → CONTACT: National Institutes of Health <grantsinfo@nih.gov>

Proposal brief

ONE LLM CALL (~1¢) · CACHED · REQUIRES STAFF KEY

Proposal shell · National Institutes of Health conventions

ONE LLM CALL (~2-3¢) · CACHED · SCAFFOLDING, NOT GHOSTWRITING

Legacy IPPRA LLM assessment (v2.0, for comparison)

15/100 · gpt-5.4-mini · 2026-07-06

This is an NIH cooperative agreement for multicenter clinical trials of natural products, focused on clinical trial coordination rather than the behavioral, policy, or population-risk research that is central to IPPRA. There is only a light public-health connection through intervention testing, and the opportunity is not aimed at the social/communication dimensions that fit IPPRA’s portfolio. Public universities are eligible, but the topic is biomedical and clinical, so it is a weak fit for IPPRA.

Legacy scoring history

2026-07-06 15 gpt-5.4-mini This is an NIH cooperative agreement for multicenter clinical trials of natural products, focused on clinical trial coordination rather than the behavioral, policy, or population-risk research that is central to IPPRA. There is only a light public-health connection through intervention testing, and the opportunity is not aimed at the social/communication dimensions that fit IPPRA’s portfolio. Public universities are eligible, but the topic is biomedical and clinical, so it is a weak fit for IPPRA.
2026-07-06 22 gpt-5.4-mini This is a clinical-trial coordination opportunity in natural products and dietary supplements, which is relevant only indirectly to IPPRA’s strengths in health communication, behavioral interventions, and community-based research. The NOFO is primarily biomedical and operational rather than policy- or social-science-centered, so IPPRA would be, at best, a limited partner rather than a lead anchor. Public universities are eligible, so there is no eligibility cap beyond the low topical fit.